These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24317180)

  • 1. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
    Yamamoto H; Higasa K; Sakaguchi M; Shien K; Soh J; Ichimura K; Furukawa M; Hashida S; Tsukuda K; Takigawa N; Matsuo K; Kiura K; Miyoshi S; Matsuda F; Toyooka S
    J Natl Cancer Inst; 2014 Jan; 106(1):djt338. PubMed ID: 24317180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Potential of Afatinib for Cancers with
    Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
    Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Recurrent Activating
    Lorch G; Sivaprakasam K; Zismann V; Perdigones N; Contente-Cuomo T; Nazareno A; Facista S; Wong S; Drenner K; Liang WS; Amann JM; Sinicropi-Yao SL; Koenig MJ; La Perle K; Whitsett TG; Murtaza M; Trent JM; Carbone DP; Hendricks WPD
    Clin Cancer Res; 2019 Oct; 25(19):5866-5877. PubMed ID: 31431454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
    Pahuja KB; Nguyen TT; Jaiswal BS; Prabhash K; Thaker TM; Senger K; Chaudhuri S; Kljavin NM; Antony A; Phalke S; Kumar P; Mravic M; Stawiski EW; Vargas D; Durinck S; Gupta R; Khanna-Gupta A; Trabucco SE; Sokol ES; Hartmaier RJ; Singh A; Chougule A; Trivedi V; Dutt A; Patil V; Joshi A; Noronha V; Ziai J; Banavali SD; Ramprasad V; DeGrado WF; Bueno R; Jura N; Seshagiri S
    Cancer Cell; 2018 Nov; 34(5):792-806.e5. PubMed ID: 30449325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.
    Tode N; Kikuchi T; Sakakibara T; Hirano T; Inoue A; Ohkouchi S; Tamada T; Okazaki T; Koarai A; Sugiura H; Niihori T; Aoki Y; Nakayama K; Matsumoto K; Matsubara Y; Yamamoto M; Watanabe A; Nukiwa T; Ichinose M
    Cancer Sci; 2017 Jun; 108(6):1263-1270. PubMed ID: 28294470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
    Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
    Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Common and Rare
    Bao R; Ng A; Sasaki M; Esai Selvan M; Katti A; Lee H; Huang L; Skol AD; Lavarino C; Salvador H; Klein RJ; Gümüş ZH; Mora J; Onel K
    Cancer Prev Res (Phila); 2021 Apr; 14(4):441-454. PubMed ID: 33419763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S490-6. PubMed ID: 24419753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.
    Ikeda K; Nomori H; Mori T; Sasaki J; Kobayashi T
    Ann Thorac Surg; 2008 Apr; 85(4):1430-2. PubMed ID: 18355544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.
    Li C; Fang R; Sun Y; Han X; Li F; Gao B; Iafrate AJ; Liu XY; Pao W; Chen H; Ji H
    PLoS One; 2011; 6(11):e28204. PubMed ID: 22140546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited lung cancer syndromes targeting never smokers.
    Yamamoto H; Yatabe Y; Toyooka S
    Transl Lung Cancer Res; 2018 Aug; 7(4):498-504. PubMed ID: 30225213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees.
    Lin H; Zhang G; Zhang XC; Lian XL; Zhong WZ; Su J; Chen SL; Wu YL
    BMC Cancer; 2020 Dec; 20(1):1209. PubMed ID: 33297998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
    Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
    J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
    Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
    Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.